Elaprase®

We have detected that your browser does not have Javascript turned on. This site is optimized for Javascript.
You may experience difficulties browsing certain parts of the site.

Genzyme Australasia Home

Genzyme Corporate Home

Genzyme Websites

Elaprase®

Elaprase^® (idursulfase) is indicated for the long term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II).

Hunter syndrome is an X-linked recessive disease caused by insufficient levels of an enzyme [iduronate-2-sulfatase (I2S)]. Due to this missing or deficient enzyme, certain complex carbohydrates progressively build up in the tissues and cells of multiple organs of the body, causing an array of debilitating symptoms. Elaprase replaces the missing enzyme needed to break down these complex carbohydrates.

Genzyme Australasia recommends patients always seek the medical advice of their healthcare professional.

Please review the Consumer Medicine Information for further details about this product.

ELAPRASE is marketed by Genzyme Australasia Pty Ltd, for the treatment of Hunter syndrome or MPS II, and manufactured by Shire Human Genetic Therapies, Inc. USA

ELAPRASE^® is a registered trademark of Shire Human Genetic Therapies, Inc

Related Information
Consumer Medicine Information


	Contact Us:
	Level 1, Building C, 12-24 Talavera Road North Ryde NSW 2113 P: 612 9978 3900 F: 612 9889 3900 Mailing Address: PO Box 282 North Ryde B/C NSW 1670 General Email Medical Enquiries Email